Jonathan Koomey
LightNews LightNews
jgkoomey.bsky.social
Jonathan Koomey
@jgkoomey.bsky.social
3.9K followers 9.2K following 2.7K posts
Climate solutions, information technology, critical thinking skills. Born at 318 ppm. https://www.koomey.com
Posts Replies Media Videos
jgkoomey.bsky.social
Excellent!
November 17, 2025 at 1:58 AM
jgkoomey.bsky.social
Do you know who made that chart? I'd love to chat with them. When the data center industry talks GW that's the planned IT maximum for the data center when it is fully built out. It won't reach that amount for years, if ever. On the other hand, it doesn't usually include cooling/infrastructure power.
November 16, 2025 at 10:13 PM
Reposted by Jonathan Koomey
mims.bsky.social
My latest on the AI bubble in finance: 6 charts that tell the story in ways that are hard to put into words.

1. U.S. data-center build-out. Notice the explosion in 2025. That's the permitting gold rush happening now. Would be shocking if 1 in 20 of these get built, but they factor into projections.
U.S. data-center build-out status by year of construction or planning, in gigawatts of capacity Chart shows that data center build-out was in the single-digit gigawatts until '21 or so, then in 22 when chatgpt happened it goes hockey stick. 2025 planned data centers are *80 gigawatts*
November 16, 2025 at 2:44 PM
Reposted by Jonathan Koomey
sailorrooscout.bsky.social
Chemists discovered a powerful hidden antibiotic that’s 100 times stronger than existing ones and effective against deadly superbugs.

The study has been published in the Journal of the American Chemical Society. YES, it is PEER-REVIEWED.
• pubs.acs.org/doi/10.1021/...

🧪🧵⬇️
Summary A team of scientists discovered a hidden antibiotic 100 times stronger than existing drugs against deadly superbugs like MRSA. The molecule had been overlooked for decades in a familiar bacterium. It shows no signs of resistance so far, offering hope in the fight against drug-resistant infections and paving the way for new approaches to antibiotic discovery. Abstract The methylenomycins are highly functionalized cyclopentanone antibiotics produced by Streptomyces coelicolor A3(2). A biosynthetic pathway to the methylenomycins has been proposed based on sequence analysis of the proteins encoded by the methylenomycin biosynthetic gene cluster and the incorporation of labeled precursors. However, the roles played by putative biosynthetic enzymes remain experimentally uninvestigated. Here, the biosynthetic functions of enzymes encoded by mmyD, mmyO, mmyF, and mmyE were investigated by creating in-frame deletions in each gene and investigating the effect on methylenomycin production. No methylenomycin-related metabolites were produced by the mmyD mutant, consistent with the proposed role of MmyD in an early biosynthetic step. The production of methylenomycin A, but not methylenomycin C, was abolished in the mmyF and mmy mutants, consistent with the corresponding enzymes catalyzing the epoxidation of methylenomycin C, as previously proposed. Expression of mmyF and mmyo in a S. coelicolor M145 derivative engineered to express mmr, which confers methylenomycin resistance, enabled the resulting strain to convert methylenomycin C to methylenomycin A, confirming this hypothesis. A novel metabolite (premethylenomycin C), which readily cyclizes to form the corresponding butanolide (premethylenomycin C lactone), accumulated in the mmyE mutant, indicating the corresponding enzyme is involved in introducing the exomethylene group into methylenomycin C. Remarkably, both premethylenomycin C and its lactone precursor were one to two orders of magnitude more active against various Gram-positive bacteria, including antibiotic-resistant Staphylococcus aureus and Enterococcus faecium isolates, than methylenomycins A and C, providing a promising starting point for the development of novel antibiotics to combat antimicrobial resistance. Graphical Abstract
November 16, 2025 at 7:32 PM